Author

N. Palacio

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1

Frequent Co-Authors

P. Penaloza-MacMaster· 3 shared S. Sanchez· 2 shared T. Ciucci· 2 shared T. Dangi· 2 shared C. S. Thaxton· 1 shared I. Koralnik· 1 shared J. Class· 1 shared J. Richner· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

P. Penaloza-MacMaster

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SARS coronavirus vaccines protect against different coronaviruses

T. Dangi, N. Palacio, S. Sanchez, J. Class, L. Visvabharathy, T. Ciucci, I. Koralnik, J. Richner, P. Penaloza-MacMaster

This study shows SARS-CoV-2 vaccines and prior coronavirus infections generate cross-reactive antibodies and T cell responses that provide protection against other coronaviruses in humans and mice.

bioRxiv · Jun 1, 2021 · PreprintImmunology

Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity

S. Sanchez, N. Palacio, T. Dangi, T. Ciucci, P. Penaloza-MacMaster

This study shows that reducing the priming dose of a SARS-CoV-2 vaccine can lead to stronger immune responses after boosting, suggesting potential benefits for vaccine distribution and design.

bioRxiv · Mar 31, 2021 · PreprintImmunology

Targeting Scavenger Receptor Type B-1 (SR-B1) and Cholesterol Inhibits Entry of SARS-CoV-2 Pseudovirus in Cell Culture

S. E. Henrich, K. M. McMahon, N. Palacio, P. Bhalla, P. Penaloza-MacMaster, C. S. Thaxton

This study shows that targeting SR-B1 with cholesterol-poor HDL nanoparticles inhibits SARS-CoV-2 pseudovirus entry in human cells.

bioRxiv · Dec 14, 2020 · PreprintMicrobiology